{
    "clinical_study": {
        "@rank": "139475", 
        "acronym": "GAMES-RP", 
        "arm_group": [
            {
                "arm_group_label": "Matching Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will receive matching placebo."
            }, 
            {
                "arm_group_label": "RP-1127 (Glyburide for Injection)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive the active agent, RP-1127 (Glyburide for Injection)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, multi-center, prospective, double blind, two-stage, adaptive study.\n      The primary objective is to demonstrate the efficacy of RP-1127 compared to placebo in\n      subjects with a severe anterior circulation ischemic stroke who are likely to develop\n      malignant edema. This objective will be addressed by comparing the proportion of RP-1127\n      treated patients and placebo treated patients with a Day 90 modified Rankin Scale (mRS) \u2264 4\n      without decompressive craniectomy (DC)."
        }, 
        "brief_title": "Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ischemic Stroke", 
            "Malignant Edema"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Gas Gangrene", 
                "Anthrax", 
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study population consists of subjects with a clinical diagnosis of acute severe anterior\n      circulation ischemic stroke, a baseline diffusion weighted image (DWI) lesion between 82 and\n      300 cm3, age 18-80 years, and time from symptom onset to start of study infusion of \u226410\n      hours. The study will enroll both patients that do not receive IV rtPA and those that\n      receive IV rtPA within 4.5 hours of stroke.\n\n      Stage 1 of the study will enroll and treat up to a maximum of 50 subjects (25 per arm) who\n      meet all inclusion/exclusion.\n\n      Enrollment will be randomized controlling for site, age \u226460 (yes/no), and IV rtPA treatment\n      at baseline (yes/no). Subjects will be randomized equally between RP-1127 and placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A clinical diagnosis of acute ischemic stroke in the MCA territory (PCA and/or ACA\n             territory involvement in addition to primary MCA territory stroke is acceptable).\n\n          -  Prior to stroke, no disability, or no significant disability despite symptoms (able\n             to carry out all usual duties and activities).\n\n          -  A baseline DWI lesion between 82 and 300 cm3 on MRI.\n\n          -  Patients treated with IV rtPA should meet established criteria for IV rtPA\n             administration in the 0-3 and 3-4.5 hr time periods at the time of rtPA\n             administration (if rtPA is administered in the 3-4.5 hr time window, the NIHSS must\n             be \u2264 25 at the time of rtPA administration).\n\n          -  The time to the start of infusion of Study Drug must be \u2264 10 hours after time of\n             symptom onset, if known, or the time last seen well [termed \"time last known at\n             neurologic baseline\" (TLK@B)].\n\n          -  Age \u226518 years and \u226480 years.\n\n          -  Provision of written informed consent by a legally authorized representative\n             according to institutional guidelines and national regulations.\n\n        Exclusion Criteria:\n\n          -  Commitment to decompressive craniectomy (DC) prior to enrollment, or following\n             enrollment and prior to start of Study Drug.\n\n          -  Treatment with intra-arterial (IA) rtPA or by mechanical means for clot disruption.\n\n          -  Patients unable to tolerate MRI scanning, e.g. those with pacemakers or automatic\n             defibrillators.\n\n          -  Evidence (clinical or imaging) of concurrent infarction in the contralateral\n             hemisphere deemed by the investigator to be sufficiently serious so as to affect\n             functional outcome.\n\n          -  Clinical signs of herniation, e.g. one or two dilated, fixed pupils; unconsciousness\n             (i.e., \u2265 2 on item 1a on the NIHSS); and/or loss of other brain stem reflexes\n             attributable to edema or herniation according to the investigator's judgment.\n\n          -  Hemorrhage (other than small petechial hemorrhages) on CT/MRI, or CT/MRI evidence of\n             anteroseptal/pineal shift greater \u22652 mm prior to enrollment that is due to cerebral\n             edema.\n\n          -  Severe renal disorder from the patient's history (e.g. dialysis) or eGFR of < 30\n             mL/min/1.73 m2.\n\n          -  Severe liver disease or ALT >3 times normal, or bilirubin >2 times normal.\n\n          -  Blood glucose <55 mg/dL at enrollment or immediately prior to administration of Study\n             Drug, or a clinically significant history of hypoglycemia.\n\n          -  Acute ST elevation myocardial infarction, and/or acute decompensated HF, and/or\n             QTc>520 ms, and/or known history of cardiac arrest (PEA, VT, VF, asystole), and/or\n             admission for an ACS, MI, or coronary intervention (PCI or coronary artery surgery)\n             within the past 3 months.\n\n          -  Known sulfonylurea treatment within 7 days. Sulfonylureas include glyburide\n             /glibenclamide (Diabeta, Glynase); glyburide plus metformin (Glucovance); glimepiride\n             (Amaryl); repaglinide (Prandin); netaglinide (Starlix); glipizide (Glucotrol,\n             GlibeneseR, MinodiabR); gliclazide (DiamicronR); tolbutamide (Orinase, Tolinase);\n             glibornuride (Glutril).\n\n          -  Known allergy to sulfa or specific allergy to sulfonylurea drugs.\n\n          -  Known G6PD enzyme deficiency.\n\n          -  Pregnant women. Women must be either post-menopausal (as confirmed by the LAR),\n             permanently sterilized or, if \u2264 50 years old must have a negative test for pregnancy\n             obtained before enrollment.\n\n          -  Breast-feeding women who do not agree (or their LAR does not agree) to stop breast-\n             feeding during Study Drug infusion and for 7 days following the end of Study Drug\n             infusion.\n\n          -  Patients already enrolled in a non-observation-only stroke study, or with\n             life-expectancy <3 months not related to current stroke, or those unlikely to be\n             compliant with follow up.\n\n          -  Patients currently receiving an investigational drug.\n\n          -  Patients in whom a peripheral IV line cannot be placed.\n\n          -  Mentally incompetent (prior to qualifying stroke) patients and wards of the state.\n\n          -  Patients who, in the opinion of the investigator, are not suitable for the study\n             (reason to be documented)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794182", 
            "org_study_id": "RPI 203"
        }, 
        "intervention": {
            "arm_group_label": "RP-1127 (Glyburide for Injection)", 
            "description": "Glyburide (5-chloro-N-(4-[N-(cyclohexylcarbamoyl) sulfamoyl]phenethyl)-2- methoxybenzamide) is an anti-diabetic medication in a class of medications known as sulfonylureas. RP-1127 is a formulation of glyburide designed for intravenous administration.", 
            "intervention_name": "RP-1127 (Glyburide for Injection)", 
            "intervention_type": "Drug", 
            "other_name": [
                "glibenclamide", 
                "glybenclamide"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Glyburide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "kdrake@neurology.arizona.edu", 
                    "last_name": "Kendra Drake"
                }, 
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85719"
                    }, 
                    "name": "University of Arizona Medical Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gregory W Albers, MD", 
                    "phone": "650-494-3848"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06510"
                    }, 
                    "name": "Yale University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Kevin N Sheth, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "scott.silliman@jax.ufl.edu", 
                    "last_name": "Scott Silliman"
                }, 
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32209"
                    }, 
                    "name": "University of Florida, Jacksonville"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Shyam K Prabhakaran, MD", 
                    "phone": "312-503-2994"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Memorial Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ann.jerde@louisville.edu", 
                    "last_name": "Ann Jerde", 
                    "phone": "502-813-6579"
                }, 
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "University of Louisville Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paul Muscat, MD", 
                    "phone": "207-883-1414"
                }, 
                "facility": {
                    "address": {
                        "city": "Scarborough", 
                        "country": "United States", 
                        "state": "Maine", 
                        "zip": "04074"
                    }, 
                    "name": "Maine Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Carolyn Cronin, 410-328-3871"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "University of Maryland School of Medicine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "wtkimberly@partners.org", 
                    "last_name": "W. Taylor Kimberly, MD, PhD", 
                    "phone": "857-238-5644"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "W. Taylor Kimberly, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Raphael A Carandang, MD", 
                    "phone": "508-334-2527"
                }, 
                "facility": {
                    "address": {
                        "city": "Worcester", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01655"
                    }, 
                    "name": "UMASS Memorial Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "turczyj@ccf.org", 
                    "last_name": "Jennifer Turczyk", 
                    "phone": "216-445-4488"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michel T Torbey, MD", 
                    "phone": "614-293-4966"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State University Wexner Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Holly E Hinson, MD", 
                    "phone": "503-418-1472"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health & Science University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "OKozak@abingtonhealth.org", 
                    "last_name": "Osman Kozak"
                }, 
                "facility": {
                    "address": {
                        "city": "Abington", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19001"
                    }, 
                    "name": "Abington Memorial Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "molyneauxbj@upmc.edu", 
                    "last_name": "Bradley Molyneaux"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "UPMC Presbyterian Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina"
                }, 
                "status": "Terminated"
            }, 
            {
                "contact": {
                    "email": "Jennifer.Majersik@hsc.utah.edu", 
                    "last_name": "Jennifer Majersik"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84132"
                    }, 
                    "name": "University of Utah Healthcare"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema", 
        "overall_contact": {
            "email": "kevin.sheth@yale.edu", 
            "last_name": "Kevin N Sheth, MD", 
            "phone": "203-785-5947"
        }, 
        "overall_contact_backup": {
            "email": "wtkimberly@partners.org", 
            "last_name": "W. Taylor Kimberly, MD, PhD", 
            "phone": "857-238-5644"
        }, 
        "overall_official": [
            {
                "affiliation": "Yale University", 
                "last_name": "Kevin N Sheth, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Massachusetts General Hospital", 
                "last_name": "W. Taylor Kimberly, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The proportion of patients with a modified Rankin Scale (mRS) at Day 90 \u2264 4 without decompressive craniectomy", 
                "safety_issue": "No", 
                "time_frame": "90 Days"
            }, 
            {
                "description": "Addressed by comparing the frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)in the RP-1127 and placebo groups, with a specific focus on all cause mortality, cardiac mortality, and cardiac-related and blood glucose-related AEs/SAEs.", 
                "measure": "Safety of RP-1127 in subjects with a severe anterior circulation ischemic stroke who are likely to develop malignant edema.", 
                "safety_issue": "Yes", 
                "time_frame": "90 Days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794182"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects that develop malignant edema", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Proportion of subjects undergoing DC, and DC-associated AEs and SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "90 Days"
            }, 
            {
                "measure": "Proportion of subjects that experience early neurological deterioration", 
                "safety_issue": "No", 
                "time_frame": "72 Hours"
            }, 
            {
                "measure": "Proportion of subjects that develop parenchymal hematomas", 
                "safety_issue": "No", 
                "time_frame": "7 Days"
            }, 
            {
                "measure": "Ipsilateral hemispheric swelling measured by MRI", 
                "safety_issue": "No", 
                "time_frame": "96 Hours"
            }, 
            {
                "measure": "Proportion of subjects with 90 day mRS 0-3 and 0-4", 
                "safety_issue": "No", 
                "time_frame": "90 Day"
            }, 
            {
                "measure": "Activities of Daily Living (as measured by the Barthel Index) at 90 days", 
                "safety_issue": "No", 
                "time_frame": "90 Days"
            }, 
            {
                "measure": "All-cause mortality at 90 days", 
                "safety_issue": "Yes", 
                "time_frame": "90 Days"
            }
        ], 
        "source": "Remedy Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Remedy Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}